Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ranitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 15/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | ATP4A | P20648 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | ATP4B | P51164 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ranitidine SCHEMBL8594797 | 1.00 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL826 | 1.00 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL824 | 1.00 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL8796367 | 1.00 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL8110889 | 0.99 | RAD52 (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL1536277 | 0.99 | ACHE (0.98) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL33298 | 0.99 | RAD52 (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL21618415 | 0.99 | ACHE (0.98) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL8488427 | 0.99 | ACHE (0.98) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL33299 | 0.99 | RAD52 (1.00) | ACHEMEN1SLC22A1ABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34122 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260115189-A1 | Combination Treatment Regimens - SMARCA2 Degrader With Taxane Anticancer Agent | PRELUDE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12601718-B2 | Method for pretreating ranitidine hydrochloride sample | Hunan Institute for Drug Inspection and Testing (CN) | 2026-04-14 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704815-A1 | A FLOATING DRUG DELIVERY SYSTEM FOR SOLID FORMS OF SALTS USED IN BOWEL CLEANSING PRODUCTS | Dark Canyon Laboratories, LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-4394516-A | Process for the preparation of a furan derivative | GLAXO GROUP LIMITED (GB) | 1983-07-19 | — | — | US | claimed |
| EP-0075141-A1 | 1,2,5-Oxadiazole-3,4-dicarboxylic-acid derivatives, process for their production, their use and pharmaceutical preparations containing them | CASSELLA Aktiengesellschaft (DE) | 1983-03-30 | — | — | EP | claimed |
| EP-0064869-A1 | Process for the preparation of a furan derivative | GLAXO GROUP LIMITED (GB) | 1982-11-17 | — | — | EP | claimed |
| US-4353902-A | HISTAMINE H2 ANTAGONIST | SMITHKLINE CORPORATION (US) | 1982-10-12 | — | — | US | claimed |
| EP-0059082-A1 | Process for the preparation of a furan derivative | GLAXO GROUP LIMITED (GB) | 1982-09-01 | — | — | EP | claimed |
| EP-0055626-A1 | Process for the preparation of a furan derivative | GLAXO GROUP LIMITED (GB) | 1982-07-07 | — | — | EP | claimed |
| EP-0055625-A1 | Process for the preparation of a furan derivative | GLAXO GROUP LIMITED (GB) | 1982-07-07 | — | — | EP | claimed |
| EP-0048626-A1 | Livestock feed | SMITHKLINE BECKMAN CORPORATION (US) | 1982-03-31 | — | — | EP | claimed |
| EP-0040489-A1 | Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine | FISONS plc (GB) | 1981-11-25 | — | — | EP | claimed |
| US-4128658-A | HISTAMINE ANTAGONISTS | ALLEN & HANBURYS LIMITED (GB) | 1978-12-05 | — | — | US | claimed |